Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease (Amped-PD)
Primary Purpose
Parkinson Disease
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Digital music therapeutic
Active-Control
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson disease, rhythmic auditory stimulation, digital therapeutics, behavior change, habits, physical activity
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic, typical Parkinson disease (based on the UK PD Society Brain Bank Criteria7) by a physician
- Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist
- 40 - 80 years of age
- Community-dwelling
- Able to walk independently without physical assistance or an assistive device for at least 10 minutes.
- Have stable PD medications for at least two weeks prior to enrollment.
- Willing and able to provide informed consent.
- Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period.
Exclusion Criteria:
- < 40 years of age
- Diagnosis of atypical Parkinsonism
- Modified Hoehn and Yahr stages 4-5
- Moderately or significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire
- History of >1 fall over the past 3 months
- Cognitive impairment (i.e., Mini-Mental State Exam Score (MMSE) < 24)
- Unable to walk independently (i.e. without physical assistance or assistive device) at a comfortable speed of 0.4m/s or greater (i.e., 10-meter Walk Test (10mWT))
- Unable to independently use the music-based digital therapeutic during training
- Significant hearing impairment
- Currently participating in physical therapy
- Currently performing regular walking exercise > 3x/week for 30 minutes per session.
- Cardiac conditions that may limit safe participation in exercise
- Orthopedic conditions that may limit safe participation in exercise
- Any other medical conditions that would preclude successful participation as determined by a physical therapist
Sites / Locations
- Center for Neurorehabilitation at Boston University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Amped-PD
Active-Control
Arm Description
6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.
6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.
Outcomes
Primary Outcome Measures
Physical activity based on the amount of moderate intensity walking
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Physical activity based on the amount of moderate intensity walking
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Physical activity based on the amount of moderate intensity walking
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Physical activity based on the amount of moderate intensity walking
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Gait quality based on variability of stride length
Stride-to-stride variability of stride lengthof the gait cycle will be measured using wearable sensors.
Gait quality based on variability of stride length
Stride-to-stride variability of stride length of the gait cycle will be measured using wearable sensors.
Gait quality based on variability of stride length
Stride-to-stride variability of stride length of the gait cycle will be measured using wearable sensors.
Gait quality based on variability of swing time
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Gait quality based on variability of swing time
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Gait quality based on variability of swing time
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Self-Report Behavioral Automaticity Index (SRBAI)
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Self-Report Behavioral Automaticity Index (SRBAI)
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Self-Report Behavioral Automaticity Index (SRBAI)
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Secondary Outcome Measures
10-Meter Walk Test (10MWT)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
10-Meter Walk Test (10MWT)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
10-Meter Walk Test (10MWT)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
6-Minute Walk Test (6MWT)
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
6-Minute Walk Test (6MWT)
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
6-Minute Walk Test (6MWT)
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
Walking cadence during in-clinic walking
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Walking cadence during in-clinic walking
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Walking cadence during in-clinic walking
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Gait velocity during in-clinic walking
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Gait velocity during in-clinic walking
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Gait velocity during in-clinic walking
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Stride length during in-clinic walking
Quantified metrics of stride length (m) will be collected using wearable sensors.
Stride length during in-clinic walking
Quantified metrics of stride length (m) will be collected using wearable sensors.
Stride length during in-clinic walking
Quantified metrics of stride length (m) will be collected using wearable sensors.
Step activity based on daily step counts
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Step activity based on daily step counts
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Step activity based on daily step counts
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Step activity based on daily step counts
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Self-Efficacy of Walking - Duration (SEW-D)
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Self-Efficacy of Walking - Duration (SEW-D)
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Self-Efficacy of Walking - Duration (SEW-D)
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Geriatric Depression Scale (GDS)
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Geriatric Depression Scale (GDS)
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Geriatric Depression Scale (GDS)
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Parkinson's Disease Questionnaire - 39 (PDQ-39)
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Parkinson's Disease Questionnaire - 39 (PDQ-39)
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Parkinson's Disease Questionnaire - 39 (PDQ-39)
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Mini Balance Evaluation Systems Test (Mini BESTest)
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Mini Balance Evaluation Systems Test (Mini BESTest)
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Mini Balance Evaluation Systems Test (Mini BESTest)
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Full Information
NCT ID
NCT05421624
First Posted
June 9, 2022
Last Updated
October 6, 2023
Sponsor
Boston University Charles River Campus
Collaborators
University of New England
1. Study Identification
Unique Protocol Identification Number
NCT05421624
Brief Title
Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
Acronym
Amped-PD
Official Title
Amped-PD: Amplifying Physical Activity Through a Novel Digital Music Therapeutic in Parkinson Disease
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boston University Charles River Campus
Collaborators
University of New England
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Regular, habitual exercise is a critical component of the long-term management of Parkinson disease (PD). However, PD-specific motor (e.g. slow and diminished movements, variable step timing) and non-motor (e.g. depression, apathy) problems collectively hinder physical activity. Rhythmic auditory stimulation (RAS) is a rehabilitation technique that employs coupling of auditory cues with movement. Walking with RAS has been shown to benefit walking rhythmicity, quality, and speed. These walking benefits make RAS advantageous in promoting moderate intensity walking activity -- an important health-objective in the management of PD. However, the therapeutic potential of RAS in self-directed walking programs has not been examined. In this pilot, we will utilize a breakthrough digital therapeutic that delivers music-adaptive RAS to alleviate PD-specific problems by regulating stepping patterns. Using music as a substrate for cue delivery, this digital therapeutic leverages gait benefits from RAS along with enjoyment of music listening, thus making it a viable and engaging modality that will yield habits of regular walking. Habits are automatically recurring psychological dispositions that emerge from repeated behaviors. The investigators posit that music cues provide recurring contextual cues that automatically evoke habitual response of exercise, thus has the potential to prompt regular physical activity. This study will enroll 44 individuals with mild-to-moderate PD. The experimental intervention, "Amped-PD", is a 6-week, user-managed community-based walking program that utilizes music-adaptive RAS that progressively increases walking intensities. This study will examine if Amped-PD (Experimental Intervention) is more effective than a standard-of-care walking program (Active-Control Intervention) in improving physical activity based on moderate intensity walking, and in improving motor deficits related to quality of walking in individuals with mild-to-moderate PD. This study will also examine whether the resultant habits formed from each intervention matter in relation to training-related changes in physical activity.
Detailed Description
Parkinson disease (PD) is the fastest growing source of disability among neurological disorders. Diminished physical activity is highly prevalent in PD and often lead to the onset of disability. Regular, habitual exercise is a critical component of the long-term PD management. However, PD-specific motor (e.g. slow and diminished movements, variable step timing) and non-motor (e.g. depression, apathy) problems collectively hinder physical activity. Rhythmic auditory stimulation (RAS) is a rehabilitation technique that employs the coupling of auditory cues with movement. When used during walking, RAS has been shown to benefit walking rhythmicity, quality, and speed. Therefore this rehabilitation technique can be advantageous in promoting moderate intensity walking activity. While clinical studies support RAS-based intervention, its translation to real-world, community-based environments and for long-term exercise for the promotion of physical activity is limited. The difference that determines viability of RAS for out-of-lab applications lie in the distinction between external entrainment (open-loop) versus autonomous entrainment (closed-loop). Open-loop RAS requires high levels of vigilance and is prone to error accumulation, which is problematic with gait dysfunction in PD. On the other hand, closed-loop RAS allows for natural and stable entrainment. A closed-loop approach in this case is a necessity of the task and a technological challenge to translate RAS to community-based settings. In this pilot, the investigators will utilize a breakthrough digital therapeutic that employs closed-loop RAS to alleviate PD-specific problems by regulating stepping patterns. Using music as a substrate for cue delivery, this digital therapeutic leverages gait benefits from RAS along with enjoyment of music listening, thus making it a viable and engaging modality that will yield habits of regular walking. The investigators posit that music that is linked to enjoyment serves as context cues that define the pre-condition to engaging in habitual walking exercise and increased physical activity. With repetition, these recurring contextual triggers (i.e. music) automatically evoke a habitual response of exercise, and thus has the potential to amplify physical activity.
The main aims of the study seek to examine if Amped-PD (Experimental Intervention) is more effective than a standard-of-care walking program (Active-Control Intervention) in improving physical activity based on moderate intensity walking (Aim 1), and in improving motor deficits related to quality of walking (Aim 2) in individuals with mild-to-moderate PD. Additionally, this study will examine whether habit formation mediates the relationship between the intervention (Amped-PD or Active-Control) and physical activity (Aim 3). The investigators hypothesize that Amped-PD will have greater improvements in amounts of moderate intensity walking and stride-to-stride variability based on stride length and swing time. Further, habit formation will be one mechanism that will explain the link between the intervention and physical activity. Secondary research aims will examine whether Amped-PD is more effective than Active-Control in improving motor and non-motor features based on short- and long-distance walking function, spatiotemporal measures of walking, step activity based on daily step counts, disease severity scores, quality of life, self-efficacy on walking, and depression.
This study will utilize the breakthrough digital music therapeutic developed and manufactured by MedRhythms (Portland, ME). To examine the effects of the intervention, the investigators will use clinical measures of motor and gait function, participant self-reports on habit formation, and quantified movement data on walking and physical activity using wearable sensors. This study will be implemented by carrying out the following study visits: (1) Primary screen over the phone, (2) Clinical Screening and Baseline Assessment, (3) Community-based, self-directed walking program (6 weeks), (3) Post-training Assessment; (4) Follow-up training (2 weeks), and (5) Final Follow-Up Assessment. Altogether, these procedures may take up to 10 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Parkinson disease, rhythmic auditory stimulation, digital therapeutics, behavior change, habits, physical activity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomly assigned to either intervention of (1) Amped-PD, or (2) Active-Control.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Amped-PD
Arm Type
Experimental
Arm Description
6-week community-based, self-directed walking program that uses a novel digital therapeutic that delivers music-adaptive rhythmic auditory stimulation.
Arm Title
Active-Control
Arm Type
Active Comparator
Arm Description
6-week community-based, self-directed walking program without using a novel digital therapeutic or any form of rhythmic auditory stimulation.
Intervention Type
Device
Intervention Name(s)
Digital music therapeutic
Other Intervention Name(s)
MedRhythms device
Intervention Description
The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.
Intervention Type
Behavioral
Intervention Name(s)
Active-Control
Intervention Description
The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
Primary Outcome Measure Information:
Title
Physical activity based on the amount of moderate intensity walking
Description
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Baseline
Title
Physical activity based on the amount of moderate intensity walking
Description
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
During training up to 4 days from start of training
Title
Physical activity based on the amount of moderate intensity walking
Description
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Physical activity based on the amount of moderate intensity walking
Description
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Gait quality based on variability of stride length
Description
Stride-to-stride variability of stride lengthof the gait cycle will be measured using wearable sensors.
Time Frame
Baseline
Title
Gait quality based on variability of stride length
Description
Stride-to-stride variability of stride length of the gait cycle will be measured using wearable sensors.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Gait quality based on variability of stride length
Description
Stride-to-stride variability of stride length of the gait cycle will be measured using wearable sensors.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Gait quality based on variability of swing time
Description
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Time Frame
Baseline
Title
Gait quality based on variability of swing time
Description
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Gait quality based on variability of swing time
Description
Stride-to-stride variability of swing time subphase of the gait cycle will be measured using wearable sensors.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Self-Report Behavioral Automaticity Index (SRBAI)
Description
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Time Frame
Baseline
Title
Self-Report Behavioral Automaticity Index (SRBAI)
Description
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Self-Report Behavioral Automaticity Index (SRBAI)
Description
The Self-Report Behavioral Automaticity Index (SRBAI) will be used to assess habit formation. This index is a patient-reported outcome that examines habit automaticity. This self-report index comprises of 12 statements with constructs spanning behavior repetition, automaticity, and identity, with responses made on 11-point Likert scales (0 = strongly disagree; 10 = strongly agree). Higher scores indicate stronger habit formation (min = 0, max = 100). Select items from this test make up the Self-Report Habit Index, which examines strength and automaticity of habits.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Secondary Outcome Measure Information:
Title
10-Meter Walk Test (10MWT)
Description
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
Time Frame
Baseline
Title
10-Meter Walk Test (10MWT)
Description
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
10-Meter Walk Test (10MWT)
Description
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
6-Minute Walk Test (6MWT)
Description
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
Time Frame
Baseline
Title
6-Minute Walk Test (6MWT)
Description
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
6-Minute Walk Test (6MWT)
Description
This is test of long-distance walking function. The participant will be asked to "cover as much distance as they safely can" for 6 minutes, and total distance is the main metric from this test.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Walking cadence during in-clinic walking
Description
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Time Frame
Baseline
Title
Walking cadence during in-clinic walking
Description
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Walking cadence during in-clinic walking
Description
Quantified metrics of walking cadence (steps/min) will be collected using wearable sensors.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Gait velocity during in-clinic walking
Description
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Time Frame
Baseline
Title
Gait velocity during in-clinic walking
Description
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Gait velocity during in-clinic walking
Description
Quantified metrics of walking velocity (m/s) will be collected using wearable sensors.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Stride length during in-clinic walking
Description
Quantified metrics of stride length (m) will be collected using wearable sensors.
Time Frame
Baseline
Title
Stride length during in-clinic walking
Description
Quantified metrics of stride length (m) will be collected using wearable sensors.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Stride length during in-clinic walking
Description
Quantified metrics of stride length (m) will be collected using wearable sensors.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Step activity based on daily step counts
Description
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Baseline
Title
Step activity based on daily step counts
Description
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
During training up to 4 days from start of training
Title
Step activity based on daily step counts
Description
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Step activity based on daily step counts
Description
Daily step counts refer to the total number of steps taken on the leg with the monitor. This will be measured using research-grade activity monitors (StepWatch Activity Monitor, Modus Health, Edmonds, WA) validated for use in PD.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
Description
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Time Frame
Baseline
Title
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
Description
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Movement Disorder Society Unified Parkinson Disease Rating Scale motor subsection (MDS-UPDRS III)
Description
The MDS UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination (33 scores summed from 18 questions) conducted by the rater. Total scores can range from 0 to 141, with higher scores indicating worse disease severity.
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Self-Efficacy of Walking - Duration (SEW-D)
Description
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Time Frame
Baseline
Title
Self-Efficacy of Walking - Duration (SEW-D)
Description
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Self-Efficacy of Walking - Duration (SEW-D)
Description
The SEW-D is a 10-item self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident).
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Geriatric Depression Scale (GDS)
Description
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Time Frame
Baseline
Title
Geriatric Depression Scale (GDS)
Description
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Geriatric Depression Scale (GDS)
Description
The GDS is a brief, self-report involving yes/no questions instrument on psychological aspects and social consequences of depression in the elderly. The short form of GDS of 15-items will be used in this study. Higher scores indicate greater depression (min = 0, max = 15).
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Parkinson's Disease Questionnaire - 39 (PDQ-39)
Description
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Time Frame
Baseline
Title
Parkinson's Disease Questionnaire - 39 (PDQ-39)
Description
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Parkinson's Disease Questionnaire - 39 (PDQ-39)
Description
The PDQ- 39 is a self-report questionnaire that assesses quality of life over the past month across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life. Lower scores reflect better quality of life (min = 0, max = 100).
Time Frame
Follow-up (up to 2 weeks post-intervention)
Title
Mini Balance Evaluation Systems Test (Mini BESTest)
Description
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Time Frame
Baseline
Title
Mini Balance Evaluation Systems Test (Mini BESTest)
Description
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Time Frame
Immediately after the intervention (up to 6 weeks)
Title
Mini Balance Evaluation Systems Test (Mini BESTest)
Description
This test comprises of 14 items that span anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait. The test has a maximum score of 28, with each item is scored from 0-2 (0 = lowest level of function, 2 = highest level of function).
Time Frame
Follow-up (up to 2 weeks post-intervention)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of idiopathic, typical Parkinson disease (based on the UK PD Society Brain Bank Criteria7) by a physician
Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist
40 - 85 years of age
Community-dwelling
Able to walk independently without physical assistance or an assistive device for at least 10 minutes.
Have stable PD medications for at least two weeks prior to enrollment.
Willing and able to provide informed consent.
Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period.
Exclusion Criteria:
< 40 years of age
Diagnosis of atypical Parkinsonism
Modified Hoehn and Yahr stages 4-5
Moderately or significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire
History of >1 fall over the past 3 months
Cognitive impairment (i.e., Mini-Mental State Exam Score (MMSE) < 24)
Unable to walk independently (i.e. without physical assistance or assistive device) at a comfortable speed of 0.4m/s or greater (i.e., 10-meter Walk Test (10mWT))
Unable to independently use the music-based digital therapeutic during training
Significant hearing impairment
Currently participating in physical therapy
Currently performing regular walking exercise > 3x/week for 30 minutes per session.
Cardiac conditions that may limit safe participation in exercise
Orthopedic conditions that may limit safe participation in exercise
Any other medical conditions that would preclude successful participation as determined by a physical therapist
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Franchino Porciuncula, PT, EdD
Organizational Affiliation
Boston University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Terry D. Ellis, PT, PhD
Organizational Affiliation
Boston University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Neurorehabilitation at Boston University
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25858971
Citation
Cavanaugh JT, Ellis TD, Earhart GM, Ford MP, Foreman KB, Dibble LE. Toward Understanding Ambulatory Activity Decline in Parkinson Disease. Phys Ther. 2015 Aug;95(8):1142-50. doi: 10.2522/ptj.20140498. Epub 2015 Apr 9.
Results Reference
background
PubMed Identifier
26876037
Citation
Ellis TD, Cavanaugh JT, Earhart GM, Ford MP, Foreman KB, Thackeray A, Thiese MS, Dibble LE. Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease. Parkinsonism Relat Disord. 2016 Apr;25:65-71. doi: 10.1016/j.parkreldis.2016.02.006. Epub 2016 Feb 2.
Results Reference
background
PubMed Identifier
24012774
Citation
Nombela C, Hughes LE, Owen AM, Grahn JA. Into the groove: can rhythm influence Parkinson's disease? Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2564-70. doi: 10.1016/j.neubiorev.2013.08.003. Epub 2013 Sep 3.
Results Reference
background
PubMed Identifier
8684391
Citation
Thaut MH, McIntosh GC, Rice RR, Miller RA, Rathbun J, Brault JM. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord. 1996 Mar;11(2):193-200. doi: 10.1002/mds.870110213.
Results Reference
background
PubMed Identifier
33040685
Citation
Hutchinson K, Sloutsky R, Collimore A, Adams B, Harris B, Ellis TD, Awad LN. A Music-Based Digital Therapeutic: Proof-of-Concept Automation of a Progressive and Individualized Rhythm-Based Walking Training Program After Stroke. Neurorehabil Neural Repair. 2020 Nov;34(11):986-996. doi: 10.1177/1545968320961114. Epub 2020 Oct 10.
Results Reference
background
PubMed Identifier
25207647
Citation
Gardner B. A review and analysis of the use of 'habit' in understanding, predicting and influencing health-related behaviour. Health Psychol Rev. 2015;9(3):277-95. doi: 10.1080/17437199.2013.876238. Epub 2014 Jan 21.
Results Reference
background
PubMed Identifier
25643222
Citation
Galla BM, Duckworth AL. More than resisting temptation: Beneficial habits mediate the relationship between self-control and positive life outcomes. J Pers Soc Psychol. 2015 Sep;109(3):508-25. doi: 10.1037/pspp0000026. Epub 2015 Feb 2.
Results Reference
background
PubMed Identifier
32083083
Citation
Wittwer JE, Winbolt M, Morris ME. Home-Based Gait Training Using Rhythmic Auditory Cues in Alzheimer's Disease: Feasibility and Outcomes. Front Med (Lausanne). 2020 Jan 31;6:335. doi: 10.3389/fmed.2019.00335. eCollection 2019.
Results Reference
background
PubMed Identifier
32255504
Citation
Jeng B, Cederberg KL, Lai B, Sasaki JE, Bamman MM, Motl RW. Step-rate threshold for physical activity intensity in Parkinson's disease. Acta Neurol Scand. 2020 Aug;142(2):145-150. doi: 10.1111/ane.13250. Epub 2020 Apr 22.
Results Reference
background
PubMed Identifier
21798044
Citation
Tudor-Locke C, Craig CL, Aoyagi Y, Bell RC, Croteau KA, De Bourdeaudhuij I, Ewald B, Gardner AW, Hatano Y, Lutes LD, Matsudo SM, Ramirez-Marrero FA, Rogers LQ, Rowe DA, Schmidt MD, Tully MA, Blair SN. How many steps/day are enough? For older adults and special populations. Int J Behav Nutr Phys Act. 2011 Jul 28;8:80. doi: 10.1186/1479-5868-8-80.
Results Reference
background
Learn more about this trial
Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
We'll reach out to this number within 24 hrs